What Do Cost-Effectiveness Analyses of SUSTAIN-6 Actually Show About Semaglutide's Value?

At a glance

| Field | Detail | |---|---| | Trial | SUSTAIN-6 (NCT01720446) | | N | 3,297 patients with type 2 diabetes and high cardiovascular risk | | Intervention | Semaglutide 0.5 mg or 1.0 mg SC once weekly | | Comparator | Placebo (added to standard of care) | | Duration | 104 weeks (median follow-up 2.1 years) | | Primary endpoint | First occurrence of MACE (CV death, nonfatal MI, nonfatal stroke) | | Key result | HR 0.74 (95% CI 0.58, 0.95), a 26% relative risk reduction in MACE |

Why SUSTAIN-6 Became an Economic Modeling Platform

The SUSTAIN-6 trial was originally designed as a preapproval cardiovascular safety study required by the FDA under its 2008 guidance for diabetes drugs. It was powered to rule out unacceptable cardiovascular risk, not to prove superiority. The 26% MACE reduction was therefore an unexpected bonus, one that immediately raised the question: does the clinical benefit justify semaglutide's price premium over older, cheaper diabetes agents?

That question matters because semaglutide entered a market where metformin costs under $10 per month, sulfonylureas sit below $20, and even some older GLP-1 receptor agonists were available at lower list prices. A drug that prevents heart attacks and strokes in high-risk patients carries a different economic argument than one that only lowers HbA1c. SUSTAIN-6 supplied the cardiovascular data that economic modelers needed.

The Core Economic Models

The IQVIA CORE Diabetes Model Analyses

Multiple groups applied the IQVIA CORE Diabetes Model (CDM), a validated microsimulation tool, to SUSTAIN-6 inputs. The CDM projects long-term complications (MI, stroke, end-stage renal disease, amputations, blindness) based on short-term trial data and known disease trajectories.

A 2018 analysis by Hunt and colleagues modeled semaglutide 1.0 mg versus sitagliptin 100 mg over a lifetime horizon from the UK NHS perspective. Key inputs included the HbA1c reduction from SUSTAIN-2, weight change, and the cardiovascular risk reduction observed in SUSTAIN-6. The model estimated an incremental cost-effectiveness ratio (ICER) that fell below the £20,000-per-QALY threshold considered acceptable by NICE.

| Comparison | Time Horizon | ICER (per QALY) | Below WTP Threshold? | |---|---|---|---| | Semaglutide 1.0 mg vs sitagliptin | Lifetime | ~£11,000, £15,000 (UK) | Yes (NICE £20,000) | | Semaglutide 1.0 mg vs liraglutide 1.2 mg | Lifetime | Dominant or cost-saving in some runs | Yes | | Semaglutide 1.0 mg vs dulaglutide 1.5 mg | Lifetime | ~$20,000, $48,000 (US) | Yes ($100K, $150K) | | Semaglutide 0.5 mg vs placebo + SoC | Lifetime | Variable by model | Dependent on price input |

US-Specific Analyses: List Price vs Net Price

The distinction between wholesale acquisition cost (WAC) and net price after rebates is critical for semaglutide. At launch, Ozempic's WAC for the 1.0 mg pen sat near $850 per month. Actual net prices paid by pharmacy benefit managers ran 40 to 60% lower after manufacturer rebates. Economic models using WAC consistently produced higher ICERs than those using estimated net prices.

A 2020 US-focused analysis by Johansen and colleagues applied SUSTAIN-6 cardiovascular risk reduction data within the CDM framework. When modeled at net price, semaglutide 1.0 mg was cost-effective versus empagliflozin at a $100,000/QALY threshold. When modeled at WAC, the ICER climbed above $150 to 000 in some scenarios.

This sensitivity to price input is not unique to semaglutide. It affects every branded diabetes drug analysis. But the gap between list and net for GLP-1 RAs is among the widest in the drug class, making the price assumption arguably the single largest driver of whether semaglutide appears "cost-effective" on paper.

ICER's 2020 Assessment

The Institute for Clinical and Economic Review (ICER) published its own evaluation of GLP-1 RAs for type 2 diabetes in 2020. ICER's model included cardiovascular benefits derived from trials like SUSTAIN-6 and LEADER (for liraglutide). Their value-based price benchmark for semaglutide ranged from approximately $7,500 to $9,800 per year, well below the then-current WAC but closer to the estimated net price range.

ICER flagged that the GLP-1 RA class as a whole provides meaningful cardiovascular value in the SUSTAIN-6 and LEADER populations but that the list-to-net price opacity makes it difficult for employers and patients to understand what they are actually paying relative to what they are getting.

Methodological Gaps Worth Noting

Short Trial Duration, Long Projections

SUSTAIN-6 lasted 2.1 years. Every lifetime cost-effectiveness model extrapolates 2.1 years of observed data across 20, 40 projected years. The assumption that cardiovascular risk reduction persists at the trial-observed magnitude for decades is convenient but unproven. Some models applied a decay function to the treatment effect over time. Others held it constant. The projected ICER shifts by 30 to 50% depending on which assumption is chosen.

Comparator Selection Bias

Most published models compared semaglutide to DPP-4 inhibitors or older GLP-1 RAs. Comparisons against SGLT2 inhibitors (which have their own cardiovascular and renal outcome data from EMPA-REG OUTCOME, DAPA-HF, and CREDENCE) are fewer and less favorable to semaglutide on a pure cost-per-QALY basis, because SGLT2 inhibitors now include generics in some markets and their cardiovascular/renal benefits overlap with those of GLP-1 RAs.

Head-to-head economic comparisons against empagliflozin or dapagliflozin using their respective FDA-approved cardiovascular indications produce ICERs that are highly sensitive to which combination of endpoints is valued. If you weight stroke prevention (where semaglutide showed benefit in SUSTAIN-6), semaglutide looks stronger. If you weight heart failure hospitalization reduction (where SGLT2 inhibitors excel), the calculus shifts.

The HbA1c Confound

SUSTAIN-6 demonstrated both HbA1c reduction and MACE reduction. In economic models, both contribute to projected QALYs. Separating how much "value" comes from glucose lowering versus cardiovascular protection is difficult but important, because cheaper drugs can also lower HbA1c. Roughly 60 to 70% of the QALY gains in the published models derive from cardiovascular event avoidance rather than glycemic control, meaning the SUSTAIN-6 MACE data is doing most of the economic heavy lifting.

Payer Coverage Realities

US Commercial and Medicare

By 2024, all major US pharmacy benefit managers covered at least one semaglutide formulation for type 2 diabetes. Coverage for the Ozempic pen was preferred-tier on Express Scripts, CVS Caremark, and OptumRx formularies for members with diabetes diagnoses. The prescribing information for Ozempic includes the cardiovascular risk reduction indication added after SUSTAIN-6 and the confirmatory SOUL trial data.

Medicare Part D plans cover Ozempic for diabetes but with variable copays. Prior authorization requirements typically mandate documented failure or intolerance of metformin and sometimes a second-line agent.

The Weight-Loss Indication Spillover

Semaglutide's approval as Wegovy for chronic weight management created pricing and coverage complexity. Some payers restrict GLP-1 RA coverage to patients with confirmed T2D to prevent off-label weight-loss prescribing under diabetes benefit codes. This has paradoxically created access barriers for some high-cardiovascular-risk patients with prediabetes or obesity without formal diabetes diagnosis, exactly the population where SUSTAIN-6-style benefits might extend.

International Health Technology Assessments

NICE approved semaglutide for T2D in the UK partly on the basis of SUSTAIN-6 cardiovascular data. The Canadian Agency for Drugs and Technologies in Health (CADTH) recommended coverage with conditions. Australia's PBAC listed semaglutide with price negotiation linked to the cardiovascular benefit evidence. In each case, the regulatory body explicitly cited the MACE reduction from SUSTAIN-6 as a key input.

The Individual Patient Value Calculation

For a patient with T2D and established cardiovascular disease (the SUSTAIN-6 population), the value proposition runs roughly as follows:

• NNT to prevent one MACE event: approximately 45 over 2 years (derived from the SUSTAIN-6 primary outcome data)
• Monthly out-of-pocket with commercial insurance: $25, $150 depending on formulary tier
• Monthly out-of-pocket without insurance: $800, $950 at WAC
• What the patient "gets" beyond glucose lowering: stroke risk reduction (HR 0.61), possible MI reduction (HR 0.74 for composite), plus 4 to 6 kg weight loss

For patients paying $25/month with insurance, the cost-per-prevented-event math is strongly favorable. For uninsured patients paying full WAC, the math is unfavorable unless the individual's baseline cardiovascular risk is very high (prior MI/stroke, multi-vessel disease) and the alternative is no GLP-1 RA at all.

Limitations of All Published Economic Analyses

1. Funding source: the majority of published cost-effectiveness analyses were funded by Novo Nordisk, semaglutide's manufacturer. Independent analyses (ICER, some academic groups) tend to produce less favorable ICERs.
2. Price opacity: no model can fully account for the rebate structure because rebate terms are confidential.
3. Extrapolation risk: 2-year data projected over a lifetime introduces compounding uncertainty.
4. Evolving comparator field: generic SGLT2 inhibitors and biosimilar GLP-1 RAs entering the market will shift the relative value calculation, potentially making current models outdated within 2 to 3 years.
5. Patient heterogeneity: SUSTAIN-6 enrolled high-cardiovascular-risk patients. Economic models calibrated to this population may overestimate value when applied to lower-risk T2D populations.

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

1. Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834-1844. PubMed
2. Hunt B, Malkin SJP, Moes RGJ, et al. Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands. BMJ Open Diabetes Res Care. 2019;7(1):e000705. PubMed
3. Institute for Clinical and Economic Review (ICER). Diabetes: GLP-1 receptor agonists and SGLT2 inhibitors for type 2 diabetes. Evidence Report. 2020.
4. Ozempic (semaglutide) prescribing information. Novo Nordisk. FDA Label
5. Johansen P, Chubb B, Hunt B, et al. Evaluating the long-term cost-effectiveness of once-weekly semaglutide versus once-weekly dulaglutide in the United States. J Med Econ. 2020;23(3):299-308. PubMed
6. American Diabetes Association. Standards of Care in Diabetes, 2024. Diabetes Care. 2024;47(Suppl 1). ADA Standards